Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
April 01, 2024 16:01 ET
|
Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...
CAR-T Funding Report 2024: Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
March 18, 2024 04:52 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024" report has been added to ...
Global Intratumoral Cancer Therapies Market Report 2023: Increasing Incidence of Cancer is Expected to Propel Growth
June 16, 2023 05:08 ET
|
Research and Markets
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Intratumoral Cancer Therapies Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
mRNA Cancer Therapies Patent Landscape 2022: Featuring BioNTech, Moderna, Novartis, Sanofi & Others
October 04, 2022 04:03 ET
|
Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering. For nearly three decades, extensive efforts...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
January 13, 2022 07:00 ET
|
Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types
October 22, 2021 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...